Atomoksetin

Atomoksetin
Klinički podaci
Drugs.com	Monografija
Način primene	Oralno
Farmakokinetički podaci
Poluvreme eliminacije	5 h
Identifikatori
CAS broj	82248-59-7
ATC kod	N06BA09 (WHO)
PubChem	CID 54841
DrugBank	DB00289
ChemSpider	49516
ChEBI	CHEBI:127342
ChEMBL	CHEMBL641
Hemijski podaci
Formula	C17H21NO
Molarna masa	255,355
	SMILES CNCC[C@@H](OC1=CC=CC=C1C)C1=CC=CC=C1; ;
	InChI InChI=1S/C17H21NO/c1-14-8-6-7-11-16(14)19-17(12-13-18-2)15-9-4-3-5-10-15/h3-11,17-18H,12-13H2,1-2H3/t17-/m1/s1 ; Key:VHGCDTVCOLNTBX-QGZVFWFLSA-N ;

Atomoksetin je organsko jedinjenje, koje sadrži 17 atoma ugljenika i ima molekulsku masu od 255,355 Da.^[1]^[2]^[3]^[4]^[5]^[6]^[7]^[8]^[9]^[10]^[11]

Osobine

Osobina	Vrednost
Broj akceptora vodonika	2
Broj donora vodonika	1
Broj rotacionih veza	6
Particioni koeficijent^[12] (ALogP)	3,6
Rastvorljivost^[13] (logS, log(mol/L))	-5,1
Polarna površina^[14] (PSA, Å²)	21,3

Reference

^ Spencer TJ, Faraone SV, Michelson D, Adler LA, Reimherr FW, Glatt SJ, Biederman J (март 2006). . „Atomoxetine and adult attention-deficit/hyperactivity disorder: the effects of comorbidity”. J Clin Psychiatry. 67 (3): 415—20. PMID 16649828.
^ Pilhatsch MK, Burghardt R, Wandinger KP, Bauer M, Adli M: Augmentation with atomoxetine in treatment-resistant depression with psychotic features. A case report. Pharmacopsychiatry. . . 39 (2): 79—80. март 2006. PMID 16555170. Недостаје или је празан параметар |title= (помоћ)
^ Carpenter LL, Milosavljevic N, Schecter JM, Tyrka AR, Price LH (октобар 2005). . „Augmentation with open-label atomoxetine for partial or nonresponse to antidepressants”. J Clin Psychiatry. 66 (10): 1234—8. PMID 16259536.
^ Kratochvil CJ, Newcorn JH, Arnold LE, Duesenberg D, Emslie GJ, Quintana H, Sarkis EH, Wagner KD, Gao H, Michelson D, Biederman J (септембар 2005). . „Atomoxetine alone or combined with fluoxetine for treating ADHD with comorbid depressive or anxiety symptoms”. J Am Acad Child Adolesc Psychiatry. 44 (9): 915—24. PMID 16113620.
^ McElroy SL, Guerdjikova A, Kotwal R, Welge JA, Nelson EB, Lake KA, Keck PE Jr, Hudson JI (март 2007). . „Atomoxetine in the treatment of binge-eating disorder: a randomized placebo-controlled trial”. J Clin Psychiatry. 68 (3): 390—8. PMID 17388708.
^ Purper-Ouakil D, Fourneret P, Wohl M, Reneric JP: [Atomoxetine: a new treatment for Attention Deficit/Hyperactivity Disorder (ADHD) in children and adolescents] Encephale. 2005 May-Jun;. . 31 (3): 337—48. PMID 16142049. Недостаје или је празан параметар |title= (помоћ)
^ Simpson D, Plosker GL: Atomoxetine: a review of its use in adults with attention deficit hyperactivity disorder. Drugs. . . 64 (2): 205—22. 2004. PMID 14717619. Недостаје или је празан параметар |title= (помоћ)
^ Montoya A, Hervas A, Cardo E, Artigas J, Mardomingo MJ, Alda JA, Gastaminza X, Garcia-Polavieja MJ, Gilaberte I, Escobar R: Evaluation of atomoxetine for first-line treatment of newly diagnosed, treatment-naive children and adolescents with attention deficit/hyperactivity disorder. . Curr Med Res Opin. 25 (11): 2745—54. новембар 2009. PMID 19785510. Недостаје или је празан параметар |title= (помоћ)
^ Gaillez C, Sorbara F, Perrin E: [Atomoxetine (Strattera), an alternative in the treatment of attention-deficit/hyperactivity disorder (ADHD) in children] Encephale. 2007 Sep;33(4 Pt 1):621-8. . . PMID 18033153. Недостаје или је празан параметар |title= (помоћ)
^ Knox, C.; Law, V.; Jewison, T.; Liu, P.; Ly, S.; Frolkis, A.; Pon, A.; Banco, K.; Mak, C.; Neveu, V.; Djoumbou, Y.; Eisner, R.; Guo, A. C.; Wishart, D. S. (2011). . „DrugBank 3.0: A comprehensive resource for 'Omics' research on drugs”. Nucleic Acids Research. 39 (Database issue): D1035—D1041. PMC 3013709 . PMID 21059682. doi:10.1093/nar/gkq1126.
^ Wishart, David S.; Knox, Craig; Guo, An Chi; Cheng, Dean; Shrivastava, Savita; Tzur, Dan; Gautam, Bijaya; Hassanali, Murtaza (2008). . „DrugBank: A knowledgebase for drugs, drug actions and drug targets”. Nucleic Acids Research. 36 (Database issue): D901—D906. PMC 2238889 . PMID 18048412. doi:10.1093/nar/gkm958.
^ Ghose, Arup K.; Viswanadhan, Vellarkad N.; Wendoloski, John J. (1998). . „Prediction of Hydrophobic (Lipophilic) Properties of Small Organic Molecules Using Fragmental Methods: An Analysis of ALOGP and CLOGP Methods”. The Journal of Physical Chemistry A. 102 (21): 3762—3772. Bibcode:1998JPCA..102.3762G. doi:10.1021/jp980230o.
^ Tetko, Igor V.; Tanchuk, Vsevolod Yu.; Kasheva, Tamara N.; Villa, Alessandro E. P. (2001). . „Estimation of Aqueous Solubility of Chemical Compounds Using E-State Indices”. Journal of Chemical Information and Computer Sciences. 41 (6): 1488—1493. PMID 11749573. doi:10.1021/ci000392t.
^ Ertl, Peter; Rohde, Bernhard; Selzer, Paul (2000). . „Fast Calculation of Molecular Polar Surface Area as a Sum of Fragment-Based Contributions and Its Application to the Prediction of Drug Transport Properties”. Journal of Medicinal Chemistry. 43 (20): 3714—3717. PMID 11020286. doi:10.1021/jm000942e.

Literatura

Hardman JG, Limbird LE, Gilman AG (2001). Goodman & Gilman's The Pharmacological Basis of Therapeutics (10. изд.). New York: McGraw-Hill. ISBN 0071354697. doi:10.1036/0071422803.
Thomas L. Lemke; David A. Williams, ур. (2007). Foye's Principles of Medicinal Chemistry (6. изд.). Baltimore: Lippincott Willams & Wilkins. ISBN 0781768799.

Spoljašnje veze

Atomoxetine

Molimo Vas, obratite pažnju na važno upozorenje
u vezi sa temama iz oblasti medicine (zdravlja).

[1] Spencer TJ, Faraone SV, Michelson D, Adler LA, Reimherr FW, Glatt SJ, Biederman J (март 2006). . „Atomoxetine and adult attention-deficit/hyperactivity disorder: the effects of comorbidity”. J Clin Psychiatry. 67 (3): 415—20. PMID 16649828.

[2] Pilhatsch MK, Burghardt R, Wandinger KP, Bauer M, Adli M: Augmentation with atomoxetine in treatment-resistant depression with psychotic features. A case report. Pharmacopsychiatry. . . 39 (2): 79—80. март 2006. PMID 16555170. Недостаје или је празан параметар |title= (помоћ)

[3] Carpenter LL, Milosavljevic N, Schecter JM, Tyrka AR, Price LH (октобар 2005). . „Augmentation with open-label atomoxetine for partial or nonresponse to antidepressants”. J Clin Psychiatry. 66 (10): 1234—8. PMID 16259536.

[4] Kratochvil CJ, Newcorn JH, Arnold LE, Duesenberg D, Emslie GJ, Quintana H, Sarkis EH, Wagner KD, Gao H, Michelson D, Biederman J (септембар 2005). . „Atomoxetine alone or combined with fluoxetine for treating ADHD with comorbid depressive or anxiety symptoms”. J Am Acad Child Adolesc Psychiatry. 44 (9): 915—24. PMID 16113620.

[5] McElroy SL, Guerdjikova A, Kotwal R, Welge JA, Nelson EB, Lake KA, Keck PE Jr, Hudson JI (март 2007). . „Atomoxetine in the treatment of binge-eating disorder: a randomized placebo-controlled trial”. J Clin Psychiatry. 68 (3): 390—8. PMID 17388708.

[6] Purper-Ouakil D, Fourneret P, Wohl M, Reneric JP: [Atomoxetine: a new treatment for Attention Deficit/Hyperactivity Disorder (ADHD) in children and adolescents] Encephale. 2005 May-Jun;. . 31 (3): 337—48. PMID 16142049. Недостаје или је празан параметар |title= (помоћ)

[7] Simpson D, Plosker GL: Atomoxetine: a review of its use in adults with attention deficit hyperactivity disorder. Drugs. . . 64 (2): 205—22. 2004. PMID 14717619. Недостаје или је празан параметар |title= (помоћ)

[8] Montoya A, Hervas A, Cardo E, Artigas J, Mardomingo MJ, Alda JA, Gastaminza X, Garcia-Polavieja MJ, Gilaberte I, Escobar R: Evaluation of atomoxetine for first-line treatment of newly diagnosed, treatment-naive children and adolescents with attention deficit/hyperactivity disorder. . Curr Med Res Opin. 25 (11): 2745—54. новембар 2009. PMID 19785510. Недостаје или је празан параметар |title= (помоћ)

[9] Gaillez C, Sorbara F, Perrin E: [Atomoxetine (Strattera), an alternative in the treatment of attention-deficit/hyperactivity disorder (ADHD) in children] Encephale. 2007 Sep;33(4 Pt 1):621-8. . . PMID 18033153. Недостаје или је празан параметар |title= (помоћ)

[10] Knox, C.; Law, V.; Jewison, T.; Liu, P.; Ly, S.; Frolkis, A.; Pon, A.; Banco, K.; Mak, C.; Neveu, V.; Djoumbou, Y.; Eisner, R.; Guo, A. C.; Wishart, D. S. (2011). . „DrugBank 3.0: A comprehensive resource for 'Omics' research on drugs”. Nucleic Acids Research. 39 (Database issue): D1035—D1041. PMC 3013709 . PMID 21059682. doi:10.1093/nar/gkq1126.

[11] Wishart, David S.; Knox, Craig; Guo, An Chi; Cheng, Dean; Shrivastava, Savita; Tzur, Dan; Gautam, Bijaya; Hassanali, Murtaza (2008). . „DrugBank: A knowledgebase for drugs, drug actions and drug targets”. Nucleic Acids Research. 36 (Database issue): D901—D906. PMC 2238889 . PMID 18048412. doi:10.1093/nar/gkm958.

[12] Ghose, Arup K.; Viswanadhan, Vellarkad N.; Wendoloski, John J. (1998). . „Prediction of Hydrophobic (Lipophilic) Properties of Small Organic Molecules Using Fragmental Methods: An Analysis of ALOGP and CLOGP Methods”. The Journal of Physical Chemistry A. 102 (21): 3762—3772. Bibcode:1998JPCA..102.3762G. doi:10.1021/jp980230o.

[13] Tetko, Igor V.; Tanchuk, Vsevolod Yu.; Kasheva, Tamara N.; Villa, Alessandro E. P. (2001). . „Estimation of Aqueous Solubility of Chemical Compounds Using E-State Indices”. Journal of Chemical Information and Computer Sciences. 41 (6): 1488—1493. PMID 11749573. doi:10.1021/ci000392t.

[14] Ertl, Peter; Rohde, Bernhard; Selzer, Paul (2000). . „Fast Calculation of Molecular Polar Surface Area as a Sum of Fragment-Based Contributions and Its Application to the Prediction of Drug Transport Properties”. Journal of Medicinal Chemistry. 43 (20): 3714—3717. PMID 11020286. doi:10.1021/jm000942e.

[1]

[2]

[3]

[4]

[5]

[6]

[7]

[8]

[9]

[10]

[11]

[12]

[13]

[14]